NICE Board Approves Landmark Changes To Increase Flexibility Of Drug Evaluation Methods And Processes In England
Industry Has Mixed Response To “Largest And Most Comprehensive Review”
Executive Summary
Big changes are in store at UK health technology assessment body NICE aimed at improving the way medicines are assessed.
You may also be interested in...
RWE Accepted As ‘Primary Evidence’ In 20% Of NICE Appraisals Over Past Year
NICE, the health technology assessment body for England and Wales, says it has seen “good uptake” of its new evaluation methods manual and real-world evidence framework, both introduced last year.
Sanofi’s Orbis-Approved GVHD Drug Rezurock Rejected For English Funding
NICE has provisionally turned down three products for funding under the National Health Service in England: Sanofi’s Rezurock for chronic graft-versus-host disease, Sobi’s lymphoma drug Zynlonta, and AstraZeneca/Daiichi Sankyo’s Enhertu for the new indication of HER2-low breast cancer.
England’s NICE Consults On Health Technology Evaluations Guide Incorporating Proportionate Approach
NICE, the health technology appraisal body for England and Wales, is asking for views on amendments to its health technology evaluations manual to incorporate its new proportionate approach to appraisals.